Liora M Schultz, MD
Pediatric Medicine · Fort Lee
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Offices
- 2
Offices
2 locations
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Schultz’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
California Medical Board record
Licence A131515 · Delinquent
Licence status: Delinquent · since 2014 · expires 2025-10-31 · University of Toronto Faculty of Medicine.
License renewal fee has not been paid. No practice is permitted.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Medicaid work
$40,836 in 2024
Medicaid paid $40,836 for 205 billed services this clinician did in 2024, up to 19 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 205 | $40,836 |
| 2024 | 205 | 1 | 19 | $40,836 |
| 2023 | 283 | 1 | 19 | $40,606 |
| 2022 | 49 | 1 | 18 | $9,098 |
| 2021 | 118 | 1 | 15 | $9,626 |
| 2020 | 96 | 2 | 13 | $10,044 |
| 2019 | 145 | 2 | 16 | $11,291 |
| 2018 | 126 | 1 | 15 | $8,729 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 283 | $40,606 |
2022
| Long return visit (40+ min) | 49 | $9,098 |
2021
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 118 | $9,626 |
2020
| Long return visit (40+ min) | 37 | $5,751 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 59 | $4,293 |
2019
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 128 | $8,944 |
| Long return visit (40+ min) | 17 | $2,347 |
2018
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 126 | $8,729 |
Money from drug and device companies
$212 in 2025
| 2025 | 1 | 2 | None | $212 |
| 2022 | 1 | 1 | None | $64 |
| 2021 | 2 | 2 | $2,820 | $2,961 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Novartis Pharmaceuticals | Kymriah | $212 | 2 payments
|
See all 2 published payments
| Novartis Pharmaceuticals | Meals · 2025-12-07 | Kymriah | $98 |
| Novartis Pharmaceuticals | Meals · 2025-09-07 | Kymriah | $114 |
See earlier years (2022, 2021)
2022: $64
| Adaptive Biotechnologies | Clonoseq | $64 | 1 payment
|
2021: $2,961
| Novartis Pharmaceuticals | Kymriah | $2,820 | 1 payment
|
| Adaptive Biotechnologies | Clonoseq | $141 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AbbVie Inc. · Venclexta · 2020 | Their institution | $58,800 |
| Celgene Corporation · Pedall Bcm-004- Pediatric All/Nhl - A Phase 1/2, Open-Label, Single Arm, Multicohort, Multicenter Trial To Evaluate the Safety and Efficacy of Jcar017 in Pediatric Subjects With Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-All) and B-C · 2024 | Their institution | $29,043 |
| Janssen Research & Development, LLC · An Open Label Multi Center Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects =1 and =30 Years of Age With Relapsed Refractory Precursor Bcell Or Tell Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma · 2021 | Their institution | $15,047 |
| Janssen Research & Development, LLC · An Open Label Multi Center Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects =1 and =30 Years of Age With Relapsed Refractory Precursor Bcell Or Tell Acute Lymphoblastic Leukemia Or Lymphoblastic Lymphoma · 2022 | Their institution | $9,408 |
Professional record
- NPI
- 1982857223
- Licence
- CA A131515California A131515: Delinquent · expires 2025-10-31
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 2080P0207X (2080P0207X); Pediatrics (208000000X)
- Mailing address
- 161 Fort Washington Ave, New York, NY, 10032
- NPI first listed
- 2008-10-30
- NPI last updated
- 2025-11-05
- NPI record certified
- 2025-11-05
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 161 Fort Washington Ave, New York, NY, 10032 · 525 E 68th St, New York, NY, 10065